Pursuant to regulation 30 of SEBI (LODR), 2015, in continuation of earlier intimation dated 02nd October, 2025, we wish to inform that the company has received revised listing approval ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Integrated Proteins Limited has received revised listing approval from BSE for 1,55,10,000 equity shares of Rs. 10 each, issued at a premium of Rs. 1.25 (total issue price of Rs. 11.25 per share) to non-promoters on a preferential basis following conversion of warrants. This is a follow-up to the company's earlier intimation dated 2nd October 2025, with BSE confirming approval on 30th September 2025. The shares will bear distinctive numbers from 3675201 to 19185200. Trading approval is still pending and will be granted only after the company files NSE listing approval (if applicable) and confirmation from NSDL/CDSL regarding crediting shares to demat accounts and lock-in of pre-preferential holdings.
This is an administrative/procedural update confirming that shares already allotted via warrant conversion are now cleared for listing on BSE, which adds to the floating supply. The very thin premium (Rs 1.25 on a Rs 10 face value) reflects a low conversion price for warrant holders. No material price catalyst expected — impact is neutral for existing shareholders apart from confirmation of the earlier equity dilution.